Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The authors report the data on the protein spectrum of blood serum, examined by DEP method in PAAG in 21 patients with ovarian and
endometrial cancer
and in 20 female-donors. Totally 27 fractions were obtained. The following differences in proteinographs of the groups under examination were revealed: protein in the patients was reliably decreased by 30-90% in the 4th, 9th, 26th fractions, and it was increased by 25-100% in the 15th, 16th, 18th and 22d fractions; 62 patients showed the fraction with Rt 2.10 in the
prealbumin
zone, which was usually absent in donor blood serum. Moreover, proteinographs from patients with malignant neoplasms of different locatization were studied comparatively. It is believed that the differnces revealed may be used for diagnostic purposes.
...
PMID:[Blood serum protein study in oncological patients]. 64 67
A histopathologic review of 1985 cases of
endometrial carcinoma
yielded 31 undifferentiated carcinomas (1.6%). Forty-eight percent were large cell type and 52%, intermediate/small cell type. Twenty-one tumors were examined immunohistochemically. All stained for keratin. Eleven tumors reacted with vimentin antibodies, two with carcinoembryonic antigen antibodies, and ten with neuron-specific enolase (NSE) antibodies (four of which stained for bombesin, two for beta-endorphin, one for
prealbumin
, five for Leu7, and four for synaptophysin). The mean age at diagnosis was 63.9 years (range, 45 to 86). The crude 5-year and 10-year survival was 58% and 48%, respectively. Seventy-nine percent of the patients in surgicopathologic Stage I and 33% in Stage II survived 5 years. The intermediate/small cell types had a somewhat better prognosis than the large cell type, but the difference was not statistically significant. The presence or absence of NSE and vimentin immunoreactivity had no influence on survival. All patients with tumors infiltrating less than one half of the myometrium survived 5 years in contrast with 46% of the patients with deep infiltrating tumors. Fifty-four percent of the patients with demonstrable vessel invasion survived 5 years in contrast with 89% not so affected.
...
PMID:Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. 204 61
Prealbumin, orosomucoid (alpha-1-acid glycoprotein), were studied by single radial immunodiffusion in sera of 216 controls and 188 patients with gynecological carcinomas divided according to diagnosis, activity, and progression of the disease. The level of orosomucoid was found higher in 94 patients with active epithelial ovarian carcinoma (mean = 1.35 g/l), in 38 women with squamous cell carcinoma of the uterine cervix (mean = 1.04 g/l), and in 56 women with
endometrial carcinoma
(mean = 0.91 g/l), than in 61 blood donors (mean = 0.62 g/l) and 155 patients with benign gynecological diseases (mean = 0.71 g/l). Orosomucoid increased with the progression of ovarian carcinoma. Patients with active localized or advanced carcinoma had higher levels of orosomucoid than patients in remission (mean = 0.88 g/l). This can help in diagnosing ovarian carcinoma relapses. Prealbumin and transferrin decreased in all women with active ovarian carcinoma and in advanced cervical and endometrial carcinomas. Transferrin and
prealbumin
of patients in remission differed from the values in advanced carcinomas of the cervix and endometrium only and cannot be used in relapse determination. Calculation of the O/P index (orosomucoid to
prealbumin
ratio) brought no advantage for tumor diagnosis in comparison with the investigation of orosomucoid alone.
...
PMID:Serum prealbumin, transferrin and alpha-1-acid glycoprotein in patients with gynecological carcinomas. 314 23